REMARKS:

This is a full and complete response to the Office action dated September 3, 2008.

EXAMINER'S RESTRICTION:

The Examiner has indicated claim 11 is generic and additionally requires restriction to and election of the one of the following asserted species:

(1) CYP4

(2) CYP52

(3) CYP102

ELECTION AND REMARKS:

Responsive to Examiner's Restriction Requirement, Applicants expressly elect CYP102 with traverse. Additionally, all pending claims 11, 12, 14-18 and 23-30 are encompassed by this election.

As a basis for the restriction requirement the Examiner has argued that the above noted species do not relate to a single general inventive concept under PCT 13.1 because, although these species are all P450 monooxygenase, each belong to a different recognized class of chemical compounds, for example mammalian, yeast, and bacteria. The Examiner therefore concludes that that each therefore have different structure and different properties, such as substrate specificity.

Applicants respectfully assert that the noted species are indeed linked to form a single general inventive concept under PCT Rule 13.1. Applicants note that even if CYP4, 52 and 102 could be further classified as suggested by the Examiner, they still do in fact share special technical features to satisfy unity of invention. As P450 enzymes, all of them contain cytochrome P450 as a functional Group, and thus are applicable to the claimed method.

Moreover, Applicants note that all of the monooxygenases of the types CYP4, 52 and 102 each have in common a similar substrate specificity. This is shown in the Table on page 10 of the application as follows:

Table 1

P450 family	Reactions of P450 enzymes
CYP1-3	Metabolization of xenobiotic substances; CYP1: PCB, PAH, dioxins, aflatoxins; CYP2: plant toxins, pesticides; CYP3: cyclosporins, erythromycin, also involved in steroid metabolism
CYP4, CYP52, CYP102	CYP4, CYP52, CYP102: terminal and/or subterminal oxidation of fatty acids CYP4: oxidation of eicosanoids (prostaglandins, leukotrienes and thromboxanes)
CYP11, CYP17, CYP21	Biosynthesis of gluco- and mineralocorticoids; CYP11: 11ß-hydroxylases, hydroxylation of deoxycorticosterone or deoxycortisol; CYP17: steroid 17α-hydroxylase; CYP21: steroid 21-hydroxylase
CYP19	Conversion of steroids into estrogens; aromatase
CYP27	Cholesterol 27-hydroxylase

Also as shown in the table above, CYP4, 52 and 102 are all in the same family. Furthermore, each of them are capable of catalyzing the terminal and/or subterminal oxidation of fatty acids.

In view of the above Applicants submit that the above noted species linked to form a single general inventive concept under PCT Rule 13.1. Accordingly, Applicants respectfully request the restriction be withdrawn.

In view of the comments above, it is respectfully requested that the rejections be withdrawn and a Notice of Allowance issue with respect to the currently pending claims.

****

The undersigned representative requests any extension of time that may be deemed necessary to further the prosecution of this application.

The undersigned representative authorizes the Commissioner to charge any additional fees under 37 C.F.R. 1.16 or 1.17 that may be required, or credit any overpayment, to Deposit Account No. 14-1437, referencing Attorney Docket No.: 50531.

In order to facilitate the resolution of any issues or questions presented by this paper, the Examiner may directly contact the undersigned by phone to further the discussion.

Novak Druce + Quigg LLP
1000 Louisiana, Fifty-Third Floor
Houston, Texas 77002
(713) 571-3400
(713) 456-2836 (fax)
Jason.bryan@novakdruce.com

Respectfully submitted,

/Jason W. Bryan/

Jason W. Bryan
Reg. No. 51,505

October 3, 2008